Anti-CA19-9 antibody [121SLE] (STJ180026)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgM
ImmunogenPrecipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le)
General Information
| Short Description | Mouse monoclonal CA19-9 antibody for use in IHC-P in human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-P |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | 121SLE |
| Isotype | IgM |
| Conjugation | Unconjugated |
| Purification | Affinity purified |
| Dilution Range | 1:100‐200 |
| Formulation | Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
| Storage Instruction | Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
Target Information
| Immunogen | Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
| Specificity | Positive control: Colon carcinoma |
Additional Info
| Background | CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewis a structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis a and/or Lewis b blood group antigens. In normal tissues, sialyl Lewis a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. |
Information sourced from Uniprot.org